Personalised Medicine—Implementation to the Healthcare System in Europe (Focus Group Discussions)

Author:

Stefanicka-Wojtas Dorota1,Kurpas Donata2

Affiliation:

1. Clinical Trial’s Department, Wroclaw Medical University, 50-556 Wroclaw, Poland

2. Family Medicine Department, Wroclaw Medical University, 51-141 Wroclaw, Poland

Abstract

Background: Personalized medicine (PM) is an approach based on understanding the differences between patients with the same disease and represents a change from the “one size fits all” concept. According to this concept, appropriate therapies should be selected for specific groups of patients. PM makes it possible to predict whether a particular therapy will be effective for a particular patient. PM will still have to overcome many challenges and barriers before it can be successfully implemented in healthcare systems. However, it is essential to remember that PM is not a medical revolution but an evolution. Methods: Three focus groups were conducted, to achieve the purpose of this study, which was to identify the barriers and facilitators existing to the implementation of PM and to highlight existing practices in European countries. Focus group discussions covered the areas of barriers and facilitators to the implementation of personalized medicine. Results: This section describes the results of the focus groups that covered the areas of barriers and facilitators of personalized medicine implementation. Conclusions: Personalized medicine faces many challenges and barriers before it can be successfully implemented in health systems. The translation of PM to European countries, differences in regulations, high costs of new technologies, and reimbursement are the reasons for the delay in PM implementation.

Funder

European Union’s Horizon 2020

Publisher

MDPI AG

Subject

Medicine (miscellaneous)

Reference19 articles.

1. (2023, January 02). Official Journal of the European Union, Council Conclusions on Personalised Medicine for Patients, (2015/C 421/03). Available online: https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:52015XG1217(01).

2. Advancing Personalized Medicine through the Application of Whole Exome Sequencing and Big Data Analytics;Suwinski;Front. Genet.,2019

3. Park, Y. (2022). Personalized Risk-Based Screening Design for Comparative Two-Arm Group Sequential Clinical Trials. J. Pers. Med., 12.

4. Precision medicine/personalized medicine: A critical analysis of movements in the transformation of biomedicine in the early 21st century;Iriart;Cad. Saude Publica,2019

5. The Future of Precision Medicine: Potential Impacts for Health Technology Assessment;Peel;Pharmacoeconomics,2018

Cited by 3 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3